TransMedics Group, Inc. (TMDX) experienced a sharp intraday decline of 24.28% on Wednesday, as the medical technology company's stock came under significant selling pressure following the release of disappointing first-quarter financial results.

The plunge was primarily driven by the company's Q1 fiscal year 2026 earnings report, which revealed a severe miss on profitability metrics. TransMedics reported adjusted earnings per share of $0.30, missing the analyst consensus estimate of $0.61 by approximately 50% and representing a 59% decline from the $0.74 reported in the same quarter last year. While revenue of $173.9 million slightly exceeded expectations, net income plummeted 72% year-over-year to $7.3 million, and the company's gross margin narrowed to 58% from 61% a year ago due to higher operating expenses including increased investments in research and development.

The earnings shortfall triggered multiple analyst downgrades and price target reductions throughout the trading session. Firms including Needham, TD Cowen, JP Morgan, Stifel, and Oppenheimer all cut their price targets on the stock, with some also lowering their ratings, reflecting heightened concerns over the company's deteriorating profit margins and earnings trajectory despite reiterated full-year revenue guidance.